Eine prognostische transkriptomische Signatur für chronische Überempfindlichkeitspneumonitis (PREDICT-HP)
Entwicklung und Validierung einer prognostischen transkriptomischen Signatur für chronische Überempfindlichkeitspneumonitis
Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
Hypersensitivity pneumonitis is an immunologically mediated form of lung disease, resulting from inhalation exposure to a large variety of antigens. For unknown reasons, a subgroup of patients with HP without a known inciting antigen exposure develops chronic disease with progressive pulmonary fibrosis (the leading cause of death). Accurately identifying patients at risk of disease progression is necessary for prognosis and therapy.
Enrolled subjects will be followed for 24 months and complete 5 visits to one of the study centers. Blood biomarkers will be collected in addition to other clinical data to determine if these biomarkers can predict disease progression.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Tucson, Arizona, Vereinigte Staaten, 85719
- University of Arizona
-
-
California
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80206
- National Jewish Health
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- University of Texas Southwestern
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84108
- University of Utah
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The study population consists of men and women aged 18 to 85 years old with a diagnosis of chronic hypersensitivity pneumonitis.
Beschreibung
Inclusion Criteria:
- Diagnosis of chronic hypersensitivity pneumonitis
- Age 18 through 85 years.
- Diagnosis of chronic hypersensitivity pneumonitis by HRCT
- Able to understand and sign a written informed consent form.
- Able to understand the importance of adherence to the study protocol and willing to follow all study requirements
Exclusion Criteria:
- Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study
- Known explanation for the interstitial lung disease
- Clinical diagnosis of any connective tissue disease
- Listed or expected to receive a lung transplant within 4 months from enrollment
- Pregnant women
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: CASE_ONLY
- Zeitperspektiven: PROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Zeit bis zum absoluten FVC-Abfall (Prognoseprozent) um ≥10 Prozent
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Zeit bis zum absoluten DLCO-Abfall (Prognoseprozent) um ≥10 Prozent
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Zeit bis zum Rückgang der relativen FVC (Prognoseprozent) um ≥10 Prozent
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Zeit bis zum Rückgang des relativen DLCO (Prognoseprozent) um ≥10 Prozent
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Zeit bis zum Rückgang des relativen DLCO (Prognoseprozent) um ≥15 Prozent
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Zeit bis zur ersten festgestellten Exazerbation einer akuten chronischen Überempfindlichkeitspneumonitis
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Notwendigkeit einer neuen Behandlung mit oralen oder intravenösen Steroiden
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Zeit bis zum Tod aus irgendeiner Ursache
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Veränderung gegenüber dem Ausgangswert bei Dyspnoe unter Verwendung des St. George's Respiratory Questionnaire Activity Score in Monat 12
Zeitfenster: 12 Monate
|
12 Monate
|
|
|
Änderung der 6-Minuten-Gehstrecke gegenüber dem Ausgangswert im 6. Monat
Zeitfenster: 6 Monate
|
6 Monate
|
|
|
Änderung vom Ausgangswert in 6-Minuten-Gehstrecke im 12. Monat
Zeitfenster: 12 Monate
|
12 Monate
|
|
|
Änderung vom Ausgangswert in 6-Minuten-Gehstrecke im 18. Monat
Zeitfenster: 18 Monate
|
18 Monate
|
|
|
Änderung vom Ausgangswert in 6-Minuten-Gehstrecke im 24. Monat
Zeitfenster: 24 Monate
|
24 Monate
|
|
|
Abnahmerate der FVC (Prognoseprozent) über 24 Monate
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Abnahmerate der FVC (ml) über 24 Monate
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Abnahmerate des DLCO (Prognoseprozent) über 24 Monate
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Abnahmerate des DLCO (mmol/min/kpa) über 24 Monate
Zeitfenster: Bis zu 24 Monate
|
Bis zu 24 Monate
|
|
|
Change from baseline in St. George's Respiratory Questionnaire total score at month 6
Zeitfenster: 6 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
6 months
|
|
Change from baseline in St. George's Respiratory Questionnaire total score at month 12
Zeitfenster: 12 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
12 months
|
|
Change from baseline in St. George's Respiratory Questionnaire total score at month 18
Zeitfenster: 18 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
18 months
|
|
Change from baseline in St. George's Respiratory Questionnaire total score at month 24
Zeitfenster: 24 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
24 months
|
|
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 6
Zeitfenster: 6 months
|
Scores range from 0 to 120, with higher scores indicating greater breathlessness. |
6 months
|
|
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 12
Zeitfenster: 12 months
|
Scores range from 0 to 120, with higher scores indicating greater breathlessness. |
12 months
|
|
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 18
Zeitfenster: 18 months
|
Scores range from 0 to 120, with higher scores indicating greater breathlessness. |
18 months
|
|
Change from baseline in dyspnea using University of California San Diego Shortness of Breath Questionnaire at month 24
Zeitfenster: 24 months
|
Scores range from 0 to 120, with higher scores indicating greater breathlessness. |
24 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 6
Zeitfenster: 6 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
6 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 12
Zeitfenster: 12 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
12 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 18
Zeitfenster: 18 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
18 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire symptoms score at month 24
Zeitfenster: 24 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
24 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire activity score at month 6
Zeitfenster: 6 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
6 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire activity score at month 18
Zeitfenster: 18 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
18 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire activity score at month 24
Zeitfenster: 24 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
24 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 6
Zeitfenster: 6 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
6 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 12
Zeitfenster: 12 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
12 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 18
Zeitfenster: 18 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
18 months
|
|
Change from baseline in dyspnea using St. George's Respiratory Questionnaire impact score at month 24
Zeitfenster: 24 months
|
The total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
24 months
|
|
Change from baseline in CT visual (≥10 percent) score at month 12
Zeitfenster: 12 months
|
Visual scores range from 0 to 100, with higher scores indicating more lung fibrosis. |
12 months
|
|
Change from baseline in CT visual (≥10 percent) score at month 24
Zeitfenster: 24 months
|
Visual scores range from 0 to 100, with higher scores indicating more lung fibrosis. |
24 months
|
|
Change from baseline in CT quantitative (≥3.4) score at month 12
Zeitfenster: 12 months
|
CT quantitative scores range from 0 to no upper limits, with higher scores indicating more lung fibrosis. |
12 months
|
|
Change from baseline in CT quantitative (≥3.4) score at month 24
Zeitfenster: 24 months
|
CT quantitative scores range from 0 to no upper limits, with higher scores indicating more lung fibrosis. |
24 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Evans Fernández, MD, MS, National Jewish Health
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- R01HL148437 (US NIH Stipendium/Vertrag)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .